Data gathered: November 23
Alternative Data for Celldex Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 4 | Sign up | Sign up | Sign up |
| Sentiment | 97 | Sign up | Sign up | Sign up |
| Webpage traffic | 13,000 | Sign up | Sign up | Sign up |
| Employee Rating | 76 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | N/A | Sign up | Sign up | Sign up |
| Facebook Followers | 140 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 3 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 9,796 | Sign up | Sign up | Sign up |
| Twitter Followers | 171 | Sign up | Sign up | Sign up |
| Twitter Mentions | 20 | Sign up | Sign up | Sign up |
| News Mentions | 1 | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 74 | Sign up | Sign up | Sign up |
| Linkedin Employees | 215 | Sign up | Sign up | Sign up |
About Celldex Therapeutics
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases.
| Price | $27.02 |
| Target Price | Sign up |
| Volume | 691,020 |
| Market Cap | $1.74B |
| Year Range | $23.31 - $44.56 |
| Dividend Yield | 0% |
| Analyst Rating | 82% buy |
| Industry | Biotechnology |
In the news
 |
HC Wainwright Reiterates Buy Rating for Celldex Therapeutics (NASDAQ:CLDX)November 22 - ETF Daily News |
|
What is HC Wainwright’s Estimate for CLDX FY2024 Earnings?November 13 - ETF Daily News |
|
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Given Average Rating of “Moderate Buy” by BrokeragesNovember 12 - ETF Daily News |
 |
Celldex Therapeutics to Present at Upcoming Investor ConferencesNovember 11 - Yahoo |
 |
Celldex Therapeutics Third Quarter 2024 Earnings: Beats ExpectationsNovember 7 - Yahoo |
 |
Celldex Therapeutics (CLDX) Reports Q3 Loss, Tops Revenue EstimatesNovember 6 - Yahoo |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 3.2M | 10M | -6.9M | -52M | -42M | -0.640 |
| Q2 '24 | 2.5M | 9.1M | -6.6M | -46M | -46M | -0.540 |
| Q1 '24 | 150,000 | 9.1M | -9M | -41M | -40M | -0.560 |
| Q4 '23 | 4.1M | 9.1M | -5M | -19M | -34M | -0.830 |
| Q3 '23 | 1.5M | 8.2M | -6.7M | -41M | -43M | -0.810 |
Insider Transactions View All
| Crowley Elizabeth filed to sell 9,074 shares at $34.9. June 18 '24 |
| Martin Samuel Bates filed to sell 28,125 shares at $35.4. June 18 '24 |
| Young Diane C. filed to sell 2,115 shares at $35.3. June 11 '24 |
| Crowley Elizabeth filed to sell 9,074 shares at $35.1. June 11 '24 |
| Jimenez Freddy A. filed to sell 25,924 shares at $33.6. June 5 '24 |
Similar companies
Read more about Celldex Therapeutics (CLDX) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, 4chan mentions, facebook engagement, facebook followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Celldex Therapeutics?
The Market Cap of Celldex Therapeutics is $1.74B.
What is the current stock price of Celldex Therapeutics?
Currently, the price of one share of Celldex Therapeutics stock is $27.02.
How can I analyze the CLDX stock price chart for investment decisions?
The CLDX stock price chart above provides a comprehensive visual representation of Celldex Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Celldex Therapeutics shares. Our platform offers an up-to-date CLDX stock price chart, along with technical data analysis and alternative data insights.
Does CLDX offer dividends to its shareholders?
As of our latest update, Celldex Therapeutics (CLDX) does not offer dividends to its shareholders. Investors interested in Celldex Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Celldex Therapeutics?
Some of the similar stocks of Celldex Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.